Enanta Pharmaceuticals Files 8-K

TL;DR

Enanta filed an 8-K on 9/30/25 for financial updates.

AI Summary

Enanta Pharmaceuticals, Inc. filed an 8-K on October 1, 2025, reporting events as of September 30, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.

Why It Matters

This filing indicates Enanta Pharmaceuticals is providing updated financial information and exhibits to the SEC, which is standard procedure for public companies.

Risk Assessment

Risk Level: low — The filing appears to be routine and does not disclose any new material risks or significant events.

Key Players & Entities

• Enanta Pharmaceuticals, Inc. (company) — Registrant
• 0001177648 (company) — Central Index Key
• 001-35839 (company) — SEC File Number
• 04-3205099 (company) — IRS Employer Identification No.
• September 30, 2025 (date) — Date of earliest event reported
• October 1, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select
• $10.00 — price to the public in the offering was $10.00 per share. In addition, Enanta granted
• $60.6 m — fering are expected to be approximately $60.6 million, after deducting underwriting dis

Filing Documents

• d81869d8k.htm (8-K) — 30KB
• d81869dex11.htm (EX-1.1) — 208KB
• d81869dex51.htm (EX-5.1) — 9KB
• g81869g73g87.jpg (GRAPHIC) — 6KB
• 0001193125-25-226828.txt ( ) — 423KB
• enta-20250930.xsd (EX-101.SCH) — 3KB
• enta-20250930_lab.xml (EX-101.LAB) — 17KB
• enta-20250930_pre.xml (EX-101.PRE) — 11KB
• d81869d8k_htm.xml (XML) — 3KB

Forward Looking Statements

Forward Looking Statements Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements about Enanta's expectations with respect to the completion of the offering and the expected net proceeds from the offering. Actual events or results may differ materially from Enanta's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering, and the impact of macroeconomic and geopolitical events. Additional factors that could cause actual results to differ materially from those stated or implied by Enanta's forward-looking statements are disclosed in Enanta's filings with the SEC, including in the section captioned "Risk Factors" in Enanta's most recent Annual Report on Form 10-K and subsequently filed Quarter Reports on Form 10-Q and the prospectus supplement relating to the offering. All forward-looking statements contained in this report speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Enanta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Item9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 1.1 Underwriting Agreement by and among Enanta Pharmaceuticals, Inc., J.P. Morgan Securities LLC, Jefferies LLC and Evercore Group L.L.C., dated September 30, 2025 5.1 Opinion of Foley Hoag LLP 23.1 Consent of Foley Hoag LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 1, 2025 ENANTA PHARMACEUTICALS, INC. By: /s/ Jay R. Luly, Ph.D. Jay R. Luly, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR